BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)

Cattrini, C.Lozano Mejorada, R.Conteduca, V.Ruiz-Vico, M.Lolkema, M. P.Lorente, D.Sandhu, S.Romero Laorden, N.Loriot, Y.Azad, A. A.Costa, L.Vinceneux, A.Kanesvaran, R.Urun, Y.Puente, J.Attard, G.Mehra, N.De Giorgi, U.Olmos Hidalgo, D.Castro Marcos, E.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26933enBRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)conference outputopen access10.1016/j.annonc.2020.08.20861569-8041http://www.annalsofoncology.org/article/S0923753420420836/pdf573469100689